Mouse Models of Type 1 Diabetes in the MICRON Literature

About the MICRON Research Literature

These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.

All publication counts and figures reflect the complete indexed research collection.

Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.

Understanding Type 1 Diabetes

Type 1 diabetes is a systemic endocrine disease: autoimmune destruction of the insulin-producing beta cells of the pancreas leaves the person insulin-deficient and chronically hyperglycemic. Its relation to the eye is that of a long-term complication.

Sustained hyperglycemia injures the retinal microvasculature and is also associated with neural and glial dysfunction in the retina. It additionally affects the cornea and lens, so the eye is one of the organs in which the damage this disease does becomes visible.

Type 1 Diabetes in Experimental Research

The retina contains a directly observable microvasculature and is neural tissue of the central nervous system, so vascular and neural effects of a systemic metabolic disease can be imaged repeatedly in the living eye. Duration of hyperglycemia is a principal exposure these experiments are built around.

How an animal is made diabetic changes what the model reproduces. Chemical induction, by streptozotocin, destroys beta cells and produces insulin deficiency and hyperglycemia without the autoimmunity that causes the human disease, and it is applied to whatever background strain the experiment otherwise calls for.

Genetic models divide further:

  • Spontaneous autoimmune diabetes in the NOD mouse and the BB rat reproduces an immune mechanism as well as the hyperglycemia
  • The Ins2Akita mouse carries a misfolded-insulin mutation that fails its beta cells without autoimmunity

What follows in a diabetic rodent eye is early non-proliferative and neurodegenerative change. These animals are not reported to progress to the proliferative retinopathy and macular edema that threaten sight in people, and the mouse and rat retina has no macula in which the second of those could arise.

A paper recorded against this disease is not for that reason a paper about retinopathy: the ocular endpoint may be retinal, corneal or lenticular, or the diabetes may be the systemic condition under which something else was measured.

Mouse Models of Type 1 Diabetes

The mouse carries most of this work.

Transgenic and knockout lines allow a pathway to be removed or overexpressed, and cost, availability, short generation time and a large body of background data reinforce the choice.

A genetic manipulation constrains rather than isolates a mechanism: developmental compensation and pleiotropy remain possible.

Published MICRON Research: Type 1 Diabetes in Mice

This page lists 25 papers from the MICRON literature, published 2013 to 2026, that study type 1 diabetes in mice.

Of these publications:

  • 25 studies used mice as the primary type 1 diabetes disease model.

Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published type 1 diabetes research.

Which imaging and experimental techniques are used in these studies?

Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.

Capabilities and Limitations of Imaging Techniques

A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications.

Optical Coherence Tomography

Optical coherence tomography provides high-resolution, cross-sectional images of ocular tissues in the living eye, allowing researchers to visualize structures at different depths. OCT is particularly useful for measuring tissue thickness, identifying structural abnormalities, and assessing the location and extent of tissue changes.

As a non-invasive imaging technique, OCT enables repeated measurements in the same eye over time, supporting longitudinal studies of disease progression and treatment response. Although OCT provides detailed structural information, it does not directly measure cellular activity or visual function. Tissue that appears structurally normal may still have functional abnormalities, making OCT a valuable companion to functional assessments such as electroretinography (ERG).

Fundus Fluorescein Angiography

Fundus fluorescein angiography uses an injected fluorescent dye to visualize blood flow through the retinal and choroidal circulation. Sequential images show how vessels fill, identify areas of reduced or absent perfusion, and reveal dye leakage associated with vascular abnormalities.

This technique is particularly useful for evaluating vascular perfusion, blood-retinal barrier integrity, and abnormal vessel growth. Fluorescein angiography primarily shows dye distribution rather than the surrounding retinal tissue. It provides a two-dimensional (en face) view in which vessels at different depths may overlap. Cross-sectional and cellular structural details require other imaging methods, such as optical coherence tomography (OCT) or optical coherence tomography angiography (OCT-A). Vascular abnormalities that do not affect dye filling or produce leakage may also remain undetected.

Electroretinography

Records the retina's electrical response to light, giving component-sensitive information about outer- and inner-retinal function. It measures function directly, which no structural method does. Full-field ERG sums across the whole retina, so a small lesion can leave the trace unchanged; focal and multifocal variants trade signal amplitude for spatial resolution.

Intravitreal Injection / Delivery

Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.

Topical Ophthalmic Drug Delivery

A compound applied as drops to the ocular surface. It is non-invasive and repeatable, so it supports frequent dosing without a procedure for each dose. What the route has to establish depends on the target: for an ocular-surface target, residence time and penetration into the surface tissue are the main barriers; for an intraocular anterior-segment target, the compound must cross ocular-surface and corneal or conjunctival barriers and reach an intraocular concentration sufficient for the experiment; for a posterior-segment target, additional ocular barriers separate the surface from the target and posterior-segment exposure is harder to establish.

Laser Photocoagulation Models

A laser lesion provokes a reproducible, quantifiable injury at a known time and place. Wavelength, power, duration, spot size, pulse mode, focus and lesion location together determine the injury produced, allowing laser exposure to be configured for different experimental endpoints. It is an induced injury, not the disease: it produces a lesion directly, bypassing the process that gives rise to comparable damage in patients.

Which MICRON systems and add-ons appear?

Which MICRON systems and add-ons appear?
Instrument Papers
MICRON IV 16
Image-Guided OCT 11
MICRON III 9
Insight Software 6
Image-Guided Focal ERG 2
Image-Guided Laser 2
Ganzfeld ERG System 1

Which strains and genetic lines are used?

Which strains and genetic lines are used?
Strain Papers Reported as
C57BL/6J 17 C57/BL6/J, C57BL/6 J, C57Bl/6J
C57BL/6 4 C57BL6
C57BL/6 (Ins2Akita) 1
C57BL/6N 1
NOD/ShiLtJ 1

Which other species appear alongside?

Which other species appear alongside?
Species Papers
Rat 3

What other conditions are recorded on the same papers?

What other conditions are recorded on the same papers?
Disease Papers
Diabetic Retinopathy 21
Diabetic Retinal Neurodegeneration 10
Diabetes Mellitus, Type 2 6
Retinal Neovascularization (General) 4
Age-Related Macular Degeneration (General) 3
Choroidal Neovascularization 2
Experimental Autoimmune Uveoretinitis (EAU) 2
Retinal Ganglion Cell Degeneration 2
Age-Related Macular Degeneration (Wet/Neovascular) 1
Color Vision Defects 1
Corneal Wound Healing 1
Leber Congenital Amaurosis (LCA) 1
Retinal Degeneration (General) 1
Retinal Detachment 1
Retinal Hemorrhage 1
Retinal Pigment Epithelium Dysfunction 1
Retinitis Pigmentosa (RP) 1
Stargardt Disease 1
Uveitis (General) 1

Which MICRON configurations appear in this work?

Configurations recorded in these papers, and the techniques recorded alongside them.

Which MICRON configurations appear in this work?
MICRON configuration Papers Most frequent techniques recorded alongside
MICRON IV 16 Optical Coherence Tomography (13), Electroretinography (7), Fundus Fluorescein Angiography (6)
Image-Guided OCT 11 Optical Coherence Tomography (11), Fundus Fluorescein Angiography (5), Electroretinography (5)
MICRON III 9 Fundus Fluorescein Angiography (7), Electroretinography (3), Intravitreal Injection / Delivery (2)
Insight Software 6 Optical Coherence Tomography (6), Fundus Fluorescein Angiography (4), Electroretinography (4)
Image-Guided Focal ERG 2 Electroretinography (2), Topical Ophthalmic Drug Delivery (2), Intravitreal Injection / Delivery (1)
Image-Guided Laser 2 Fundus Fluorescein Angiography (2), Laser Photocoagulation Models (1), Optical Coherence Tomography (1)
Ganzfeld ERG System 1 Electroretinography (1), Intravitreal Injection / Delivery (1), Optical Coherence Tomography (1)

The papers

The papers
Year Title Journal Role of focal species MICRON products Links
2026 Crop-OCT: a Fully Integrated Imageomics Pipeline to Identify Regional and Focal Retinopathy in Murine Models bioRxiv Disease model Image-Guided OCT, MICRON IV DOI · reSEARCH
2025 N-acetyl-l-cysteine ethyl ester (NACET) induces the transcription factor NRF2 and prevents retinal aging and diabetic retinopathy. Redox Biology Disease model Image-Guided OCT, Insight Software, MICRON IV DOI · reSEARCH
2025 Non-invasive bioelectrical therapy suppresses retinal neovascularization by modulating cellular metabolism and inflammation. Cell Communication and Signaling Disease model Image-Guided Laser, MICRON IV DOI · reSEARCH
2025 Enhanced M2 Polarization of Retinal Microglia in Streptozotocin-Induced Diabetic Mice upon Autoimmune Stimulation. Biomedicines Disease model Image-Guided OCT, MICRON IV DOI · reSEARCH
2025 Leucine-rich α-2-glycoprotein 1 initiates the onset of diabetic retinopathy in mice. Science Translational Medicine Disease model MICRON III DOI · reSEARCH
2024 α-Klotho prevents diabetic retinopathy by reversing the senescence of macrophages. Cell Communication and Signaling Disease model Ganzfeld ERG System, MICRON IV DOI · reSEARCH
2024 Autoimmune uveitis attenuated in diabetic mice through imbalance of Th1/Th17 differentiation via suppression of AP-1 signaling pathway in Th cells. Frontiers in Immunology Disease model MICRON IV DOI · reSEARCH
2024 Optimal Humanized Scg3-Neutralizing Antibodies for Anti-Angiogenic Therapy of Diabetic Retinopathy. International Journal of Molecular Sciences Disease model Image-Guided Laser, MICRON IV DOI · reSEARCH
2023 Sustained Upregulation of Endothelial Nox4 Mediates Retinal Vascular Pathology in Type 1 Diabetes. Diabetes Disease model MICRON III DOI · reSEARCH
2023 Peroxisome proliferator-activated receptor-α (PPARα) regulates wound healing and mitochondrial metabolism in the cornea. Proceedings of the National Academy of Sciences of the United States of America Disease model MICRON IV DOI · reSEARCH
2023 The Slow Progression of Diabetic Retinopathy Is Associated with Transient Protection of Retinal Vessels from Death. International Journal of Molecular Sciences Disease model Image-Guided OCT, Insight Software, MICRON IV DOI · reSEARCH
2023 Sodium butyrate ameliorates diabetic retinopathy in mice via the regulation of gut microbiota and related short-chain fatty acids. Journal of Translational Medicine Disease model Image-Guided OCT, MICRON IV DOI · reSEARCH
2021 Short-and Long-Term Expression of Vegf: A Temporal Regulation of a Key Factor in Diabetic Retinopathy. Frontiers in Pharmacology Disease model Image-Guided OCT, Insight Software, MICRON IV DOI · reSEARCH
2020 Role of Endothelial ADAM17 in Early Vascular Changes Associated with Diabetic Retinopathy. Journal of Clinical Medicine Disease model MICRON III DOI · reSEARCH
2020 Treatment of diabetic retinopathy through neuropeptide Y-mediated enhancement of neurovascular microenvironment. Journal of Cellular and Molecular Medicine Disease model Image-Guided Focal ERG, MICRON IV DOI · reSEARCH
2020 Pathogenic Role of PPARα Downregulation in Corneal Nerve Degeneration and Impaired Corneal Sensitivity in Diabetes. Diabetes Disease model MICRON III DOI · reSEARCH
2019 Homocysteine: A Potential Biomarker for Diabetic Retinopathy. Journal of Clinical Medicine Disease model Image-Guided OCT, MICRON III DOI · reSEARCH
2019 Functional Regulation of an Oxidative Stress Mediator, Rac1, in Diabetic Retinopathy. Molecular Neurobiology Disease model Image-Guided OCT, Insight Software, MICRON IV DOI · reSEARCH
2019 Intravitreal injection of adenosine A2A receptor antagonist reduces neuroinflammation, vascular leakage and cell death in the retina of diabetic mice. Scientific Reports Disease model Image-Guided OCT, Insight Software, MICRON IV DOI · reSEARCH
2018 Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: Modelling signs of diabetic retinopathy. PLoS ONE Disease model Image-Guided OCT, MICRON IV DOI · reSEARCH
2018 The NLRP3 Inflammasome May Contribute to Pathologic Neovascularization in the Advanced Stages of Diabetic Retinopathy. Scientific Reports Disease model Image-Guided OCT, Insight Software, MICRON IV DOI · reSEARCH
2018 Iron Overload Accelerates the Progression of Diabetic Retinopathy in Association with Increased Retinal Renin Expression. Scientific Reports Disease model MICRON III DOI · reSEARCH
2015 The Neuropilin-1 Inhibitor, ATWLPPR Peptide, Prevents Experimental Diabetes-Induced Retinal Injury by Preserving Vascular Integrity and Decreasing Oxidative Stress. PLoS ONE Disease model Image-Guided Focal ERG, MICRON III DOI · reSEARCH
2013 The effects of age and Cx3cr1 deficiency on retinal microglia in the Ins2(Akita) diabetic mouse. Investigative Ophthalmology & Visual Science Disease model MICRON III DOI · reSEARCH
2013 Retinal angiogenesis in the Ins2(Akita) mouse model of diabetic retinopathy. Investigative Ophthalmology & Visual Science Disease model MICRON III DOI · reSEARCH

Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.

Last built 2026-11-10 from content tag hubs-content-2026-11-10 (ae06cfc); fact-sheet run sheets-20261110T111119Z. About these hubs Back to top